Tirzepatide Injection — first-in-class once-weekly GIP/GLP-1 dual receptor agonist delivering superior HbA1c reduction and weight loss in ty
Tirzepatide Injection — first-in-class once-weekly GIP/GLP-1 dual receptor agonist delivering superior HbA1c reduction and weight loss in type 2 diabetes and obesity. GMP manufactured by Artemisine Medicines Technology with COA, COPP, DMF and CTD dossiers.
| Product Name | Tirzepatide Injection (GIP/GLP-1 Dual Agonist) |
|---|---|
| Dosage Form | Injection |
| Strength | 2.5 mg–15 mg per 0.5 mL — single-dose prefilled pen |
| Standards | BP / ENTERPRISE |
| Packing | Single-dose prefilled pen, 4 pens/box; cold-chain 2–8°C shipping |
| Documents | COA, COPP, DMF, CTD Dossiers |
| MOQ | Contact us for MOQ and current stock |
Reference information summarised from WHO prescribing guidance. Expand each item below — clinical use must always follow the locally approved product insert.
Reference: WHO Model Formulary / WHO Model List of Essential Medicines. For professional reference only — clinical use must follow the locally approved product insert and national treatment guidelines.
Full batch testing and quality traceability under standard GMP workshops.
Sufficient stock on regular items, familiar with export logistics to 50+ countries.
COA, DMF, dossier and legalization documents for your market registration.